disturbances reduce quality of life, impair daytime functioning, and are associated with motor vehicle crashes. [5] [6] [7] Chronic sleep disturbances, coupled with the adverse effects of medications prescribed for PD and sleep, limit the usefulness of available treatment strategies. Therefore, there is a great need to develop nonpharmacological approaches to preventing and managing sleep disorders in patients with PD. In PD, the cause of sleep disturbances has largely been attributed to the symptoms, 8, 9 adverse effects of medications, 10 and primary neurodegeneration of central sleep regulatory areas. 11 Disruption of circadian rhythms, which can also result in sleep fragmentation and daytime somnolence, 12, 13 has not been well studied in PD, but a growing body of evidence suggests significant alterations of the circadian system. 14, 15 Circadian rhythms are endogenous physiologic cycles that occur on approximately a 24-hour cycle and are generated by a circadian pacemaker located in the suprachiasmatic nucleus of the hypothalamus. 16, 17 Circadian rhythms are synchronized to the environmental light or dark and to social activity cycles by zeitgebers (time givers). 18 Light represents the most effective zeitgeber of the circadian timing system. 19, 20 Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy older people and patients with dementia, 21 and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. A few exploratory studies have examined the effects of supplemental light exposure in PD and documented significant improvements in depression, bradykinesia, rigidity, dyskinesias, and insomnia symptoms. [22] [23] [24] The purpose of this study was to assess the safety and efficacy of light therapy (LT) as a novel treatment approach to excessive daytime sleepiness (EDS) associated with PD.
Methods

Study Design
This trial was a randomized, placebo-controlled, clinical intervention of LT in patients with PD and coexistent EDS. Participants with PD who had an Epworth Sleepiness Scale (ESS) score of 12 or greater were randomized to receive a 2-week LT intervention using either bright light exposure of 10 000 lux (active group) or dim-red light exposure of less than <300 lux (controlled group) ( Figure) . The study protocol (available in the Supplement) was approved by the institutional review boards of Northwestern University, Chicago, Illinois, and Rush University, Chicago. All study participants provided written informed consent.
Study Population
Thirty-one patients were recruited from the Parkinson's Disease and Movement Disorders Centers at Northwestern University and the Parkinson's Disease and Movement Disorders Program at Rush University. Patients were enrolled in the study if they (1) had a diagnosis of idiopathic PD, as defined by the UK Parkinson's Disease Society Brain Bank Criteria; (2) were classified as Hoehn and Yahr stages 2 to 4; (3) had EDS, as defined by an ESS score of 12 or greater; (4) had a stable PD medication regimen for at least 4 weeks before study screening; and (5) were willing and able to give written informed consent. Patients were excluded from participation if they (1) had atypical parkinsonian syndrome; (2) had significant sleepdisordered breathing, defined as an apnea-hypopnea index of more than 15 events per hour of sleep on screening polysomnography; (3) had significant periodic limb-movement disorder, defined as a periodic limb-movement arousal index of more than 10 events per hour of sleep on screening polysomnography; (4) had REM (rapid eye movement) sleep behavior disorder based on the presence of both clinical symptomatology and intermittent loss of REM atonia on screening polysomnography; (5) had cognitive impairment, as indicated by a Mini-Mental State Examination score less After the screening, eligible participants entered a 2-week baseline phase. They wore an actigraphy monitor (Actiwatch-2; Philips Respironics), on the nondominant wrist for 24 hours a day, 7 days a week. The monitor recorded activity in epochs of 1 minute, and a photosensor integrated into the monitor recorded light exposure. Participants completed a daily sleep log, in which they noted bedtime, wake-up time, estimated total sleep time, sleep latency, wake after sleep onset, naps, and sleep quality. A visual analog scale (VAS) score for daytime sleepiness was completed every 2 hours on Mondays, Wednesdays, and Fridays, starting at 8 AM until the habitual bedtime.
After the baseline phase, participants were randomized to bright LT or dim-red LT (control condition). Participants received 1 hour of bright LT or dim-red LT in gaze direction in the morning (9) (10) (11) and in the afternoon (5-7 PM) daily for 2 weeks. A light box (SunRay; The SunBox Co) was used for LT administration. The box was placed 86.4 cm away from the subject, and an 86.4-cm string attached from its side, along with detailed instructions provided to the participants, assisted with the proper exposure distance. Participants were instructed to sit quietly during LT and not to nap, and they were allowed to listen to music or audiobooks. They also recorded light exposure duration and timing daily in a light log. During the intervention phase, participants continued to wear the actigraphy monitor, maintained sleep logs, and completed the VAS for daytime sleepiness.
To examine potential carryover effects of the initial responses to LT, we had all participants continue to wear the actigraphy monitor, maintain sleep logs, and complete the VAS for daytime sleepiness for an additional 2 weeks after the conclusion of the intervention phase. The final study visit was performed after this 2-week follow-up period. One study rater (A.V.) remained blinded to the participants' LT assignment throughout the study. Data were collected from March 1, 2007, through October 31, 2012.
Statistical Analysis
The primary outcome measure was the change in the ESS when comparing the bright light exposure with dim-red light exposure. Secondary outcome measures included the global Pittsburgh Sleep Quality Index score, Parkinson's Disease Sleep Scale score, VAS scores for daytime sleepiness, and sleep logderived and actigraphy-derived metrics. A variety of exploratory analyses examined the effects of bright light exposure on the Fatigue Severity Scale, the Beck Depression Inventory, quality of life, cognition, mood, and motor disability.
Efficacy analyses were performed from November 1, 2012, through April 30, 2016, using intention-to-treat analysis. The distribution of the change scores of the treatment groups was compared using a 2-sample t test. Actigraphy measures were calculated using Actiware software, version 5.71 (Mini-Mitter Co), and checked against the daily sleep logs maintained by the participants. Two-factor, repeated-measures, one-way analysis of variance, with day of study as the within-subject factor and group membership as the between-subject factor, was conducted for actigraphy output measures. Adverse events were described.
With 12 participants per treatment group completing the study protocol, there was 80% power against an effect size of 1.1 (α = .05, 2-sided, 2-sample t test). This corresponds to a mean difference in change scores of 4.6 on the ESS, with a projected within-group SD of 4 points. The projection is conservatively based on a study of modafinil for the treatment of EDS in patients with PD. 25 
Results
Patient Characteristics
Fourteen participants failed the screening because they had an ESS score of more than 12 (n = 5), presence of obstructive sleep apnea (n = 4), a Mini-Mental State Examination score lower than 24 (n = 3), and medication changes (n = 2). Thirtyone participants (13 males and 18 females) with a mean (SD) disease duration of 5.9 (3.6) years (range, 32-77 years) were enrolled. All participants completed the study. There were no significant differences in demographic characteristics, disease duration and severity, metrics of sleep and alertness, and other disease characteristics between the active treatment group and control group ( Table 1) . No medication changes occurred throughout the study.
Adherence Metrics
The total LT exposure for this experimental protocol is 28 hours divided in 2 sessions daily for 14 days. The mean (SD) selfreported use of LT in participants treated with bright LT was 20.8 (5.3) hours (range, 10.3-27.4 hours) and 21.8 (6.0) hours (range, 7-28 hours) in participants treated with dim-red LT.
Effects of LT as Self-reported or Assessed in Questionnaires or Scales
Bright LT resulted in significant improvements in EDS, assessed by the ESS score ( Table 2 ). Both bright LT and dim-red LT were associated with improvements in sleep quality as as-sessed by the Pittsburgh Sleep Quality Index. The Parkinson's Disease Sleep Scale captured improvements in sleep after LT in both study groups (Table 2 ). These beneficial effects of LT on 3 self-reported markers of sleep and alertness were not present 2 weeks after cessation of LT. Light therapy improved self-reported alertness (VAS measures) in the bright LT group.
Effects of LT as Self-reported in Sleep Diaries
Light therapy improved multiple sleep metrics as assessed by participant-reported sleep diaries: Overnight awakenings, sleep quality, and ease of falling asleep were all significantly improved in participants treated with bright LT (Table 3) . Sleep latency, total sleep time, and wake time after sleep onset be- came shorter with the administration of either bright LT or dimred LT. All participants reported being more refreshed in the morning during LT, compared with the baseline status. Actual light brightness (95th percentile) was positively related to the measure wake time during night and negatively related to the measure dreaming.
Effects of LT on Actigraphy-Derived Measures of Sleep-Wake Cycles
During actigraphy-defined sleep, sleep-onset latency diminished after the completion of bright LT and remained improved at the final study visit following the completion of the washout period ( Table 4) . Although actigraphy-derived sleep efficiency did not change after LT, total physical activity counts and the average physical activity counts became higher in both lighting conditions. During actigraphy-defined wake, both types of LT were associated with significant increases in total physical activity counts that persisted at the end of the washout period (Table 4) . Bright LT was associated with higher average physical activity count, compared with dim-red LT. The percentage of scored sleep time during the wake interval diminished in both LT groups.
Effects of LT on Disease Severity and Other Metrics
Light therapy led to improvements of disease severity as assessed by the UPDRS (Table 2) ; it was associated with significant improvements in the total UPDRS score and in the UPDRS parts I, II, and III scores ( Table 2) . No significant differences in the total and composite UPDRS scores were observed between the 2 LT arms. After the washout period, the favorable effect of LT persisted in the domain of activities of daily living as assessed by the UPDRS part II. Light therapy was not associated with significant changes in depression, anxiety, or quality of life.
Adverse Effects of LT
Light therapy was well tolerated. Within the bright LT group, 2 study participants reported 1 adverse effect each: headache and sleepiness. One participant in the dim-red LT group reported itchy eyes. These adverse effects resolved spontaneously.
Discussion
Light therapy is a noninvasive, nonpharmacological, welltolerated intervention widely available and used as a treatment modality for several sleep and psychiatric disorders. This treatment modality is relatively easy to prescribe and incorporate into a clinical practice. Important aspects of LT are the timing of its administration and the spectral properties of the light applied in a specific LT regimen. The timing of LT is important because it may affect the circadian phase, causing either phase advance or delay. These changes are most likely to occur if LT is administered soon after the habitual wake time or in close proximity to the habitual sleep time. Bright LT remains the main treatment modality, but other wavelengths, such as blue and green lights, have been used as well.
In this study, we assessed the effects of timed LT on sleep and alertness and explored LT's effects on motor and nonmotor manifestations and the quality of life for patients with PD. To our knowledge, this is the first study to target impaired sleep-wake cycles in PD with LT intervention. We used dimred LT as the placebo arm because dim-red light has been accepted as an appropriate experimental control condition in studies of LT. 26 The LT improved several metrics of sleep and excessive sleepiness. It was the most beneficial in enhancing daytime alertness and sleep quality. Daytime sleepiness (as assessed by the ESS) and sleep quality, latency, and fragmentation (as as- sessed by self-reported sleep diaries) were significantly better in the bright LT group than in the dim-red LT group. Sleep latency (captured by sleep diaries) and overall sleep quality (assessed by the Parkinson's Disease Sleep Scale and Pittsburgh Sleep Quality Index) improved in both treatment arms. After the 2-week washout period, sleep diary-assessed sleep fragmentation as well as actigraphy-assessed wake after sleep onset and sleep latency remained improved compared with the baseline status. These results are encouraging and relevant because sleep fragmentation and EDS are frequently present in patients with PD and represent a substantial portion of nonmotor PD symptoms with unmet therapeutic needs. Of interest are the improvements in PD severity. These include improvements (which were present in both study arms after the LT intervention) in UPDRS total score and individual scores in parts I, II, and III. The UPDRS part II score remained better after the washout period than the baseline status score. This part is reflective of PD-specific effects on activities of daily living; therefore, it is encouraging to report potential benefits of LT on activities of daily living of patients with PD.
Light therapy was well tolerated, and the participants' adherence to the study protocol was excellent. This finding is in agreement with results reported in the available literature on LT, which documented mild and transient side effects, including headache, nausea, and hypomania. 27 A few other studies examined the effects of supplemental light exposure on PD. In a pilot study of 36 patients with PD, Paus and colleagues 24 administered bright light of 7500 lux and 950 lux (control condition) for 30 minutes in the morning for 14 days. These investigators observed significant improvements in tremor; UPDRS parts I, II, and IV; depression; and sleepiness. The control they used might not have been a true placebo because its intensity may have had active properties. In a case series of 12 patients with PD, white fluorescent light was administered for 1 to 1½ hours at an intensity of 100 to 1500 lux 1 hour before habitual sleep time. 23 Within 2 weeks of that treatment, bradykinesia and rigidity were improved. With ongoing LT administration, improvements were noted in agitation, dyskinesias, and psychiatric symptoms with concomitant reduction of dopaminergic therapy. In an openlabel study, 28 120 patients with PD were prescribed bright LT at the dose of 4000 to 6000 lux for 60 minutes before habitual bedtime; these patients were followed up from a few months to 8 years. Patients with good adherence to the therapy achieved enhancements in mood, anxiety, and motor function. Several metrics of sleep, alertness, and motor PD severity improved in both LT arms of this study. One possible explanation for these findings is the placebo effect. Another possibility may be that a relatively short duration of light exposure LT exposure has to be at least 6 to 8 weeks for its beneficial effects to emerge. Another possible reason is that some individuals in the control group still had significant daily exposure to ambient bright light during the day (at times different from the LT times). Finally, anchoring the LT to a strict twicedaily regimen provided means for structuring daily activities, which itself may be an interesting possible mechanism underlying the beneficial effects of both bright LT and dim-red LT, given that a regular sleep-wake cycle may feed back to increase the amplitude of the circadian oscillator. Emerging experimental evidence suggests that behavioral manifestations of circadian disturbances may be modulated by a social context in which lifestyle factors contribute to symptom onset and manifestations. 29 There is no consensus on the optimal timing, dosage, and treatment duration for LT. We applied LT with 10 000 lux in the active arm. Most commonly used light intensities are between 2500 lux and 10 000 lux, administered in bursts of 1 to 2 hours. 30 Exploratory studies in patients with PD used light intensity of 1000 to 7500 lux. 23, 24 Furthermore, light intensity of 1000 lux has been confirmed to synchronize rhythms in healthy people 31 and to improve circadian rhythm abnormalities in older patients with dementia. 32 Future studies of LT in the PD population need to address the optimal treatment parameters of LT. The mechanisms that underlie the effects of LT on PD observed in this study are not clear. Light therapy may be exhibiting its therapeutic benefits through direct alerting effects. 33 This mechanism could explain more the improvements in daytime alertness and less the benefits on sleep and motor symptoms. Another plausible mechanism of action is the potential influence on the circadian system. Activation of the suprachiasmatic nucleus has been hypothesized as one mechanism of bright light effects on mood, sleep, and circadian rhythm. 34, 35 Emerging evidence reveals dampening of the amplitude of the circadian system in PD. 36 Parkinson disease is also associated with decreased exposure to environmental light and a decline in retinal function, which collectively reduce the input of the main alerting signal-bright light-to the suprachiasmatic nucleus. 37 Light exposure via its effects on the circadian pathways may strengthen circadian signal and improve consolidation of sleep-wake cycles in PD.
Limitations
A major limitation of this study was that light levels were not measured at other times of the day. Therefore, some individuals in the dim-red LT goup received as much or more light exposure (from nonlightbox lighting sources) than those under the bright LT group. To adjust for this difference, we performed some analyses using the light levels recorded by the actigraphy monitors. However, this difference in exposure may have affected our ability to find differences between the groups. Future studies may be more strict in controlling such exposures.
Conclusions
Light therapy is a well-tolerated, feasible intervention for impaired sleep-wake cycles associated with PD. Bright LT was associated with improvements in EDS, sleep fragmentation, and sleep quality. Light therapy may also be beneficial for motor symptoms of PD. Based on these results, the next logical step is to optimize various parameters of LT (eg, intensity, duration, and wavelength) not only for impaired sleep and alertness but also for other motor and nonmotor manifestations of PD. Such chronobiological treatment strategies would be highly desirable because pharmacological interventions for sleep disturbances in PD have been of modest benefit and may cause unacceptable side effects. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
BACKGROUND AND SIGNIFICANCE
Sleep disturbances are common in Parkinson's disease (PD). In particular, excessive daytime sleepiness and nocturnal sleep fragmentation are frequently observed sleep complaints, affecting up to 90% of advanced PD patients [1, 2] . Sleep disturbances reduce quality of life, impair daytime functioning, and are associated with motor vehicle accidents in PD [3] [4] [5] . The chronic nature of sleep disturbances in PD, coupled with the side effects of medications, limits the usefulness of pharmacological treatment strategies. Therefore, there is a great need to develop non-pharmacological treatment approaches for the prevention and management of sleep disorders in PD population.
The etiology of sleep disturbances in PD has largely been attributed to the symptoms of PD [6, 7] , side effects of antiparkinson medications [8] , and primary neurodegeneration of central sleep regulatory areas [9] . However, disruption of circadian rhythms, which can also result in sleep fragmentation and daytime somnolence [10, 11] , has not been well studied in PD population.
Circadian rhythms are physiologic or behavioral cycles that occur on a 24-hour cycle, and are generated by a circadian pacemaker located in the suprachiasmatic nucleus of the hypothalamus [12, 13] . Circadian rhythms are synchronized (entrained) to the environmental light/dark and social/activity cycles by so called "zeitgebers" (German for "time-giver") [14] . Light represents the most effective zeitgeber of the circadian timing system [15, 16] .
There is a negative correlation between environmental light intensity and sleep disturbances in the elderly [17] [18] [19] . Older people are exposed to reduced illumination levels in their daily lives, but have a maintained responsiveness of the circadian pacemaker to light [20] . Supplementary exposure to morning bright light has shown beneficial effects on sleep quality and daytime vigilance [21] [22] [23] . Therapeutic exposure to bright light has also been shown to consolidate sleepwake cycle and rest-activity rhythms in patients with dementia [24] [25] [26] [27] [28] [29] .
To the best of our knowledge only one short-term study examined the effects of bright light exposure in PD population [30] . In this study, 40 PD patients were exposed to bright light, with subsequent decrease in rigidity and bradykinesia and improvement in overall motor function. We are not aware of any study that assessed the effects of bright light exposure on daytime sleepiness and nocturnal sleep in PD population.
Clear guidelines for the optimal dosing and duration of light therapy do not exist. Most commonly used light intensities are between 2,500 to 10,000 lux, administered in burst of 1 to 2 hours [31] . Side effects are mild and transient, and include headache, nausea, vomiting, and hypomania [32] .
Chronobiologic strategies, such as bright light could potentially improve sleep related impairments in daytime function in PD patients. Such behavioral strategies would be highly desirable since pharmacological interventions for sleep disturbances in PD have been of modest benefit, and may cause unacceptable side effects [33] .
HYPOTHESIS
Bright light exposure will diminish daytime sleepiness and improve night-time sleep in PD patients with daytime sleepiness.
SPECIFIC AIMS
1. to assess the effects of bright light treatment on daytime sleepiness and nocturnal sleep in PD patients with daytime sleepiness 2. to assess the feasibility and tolerability of bright light therapy in PD patients with daytime sleepiness.
STUDY DESIGN
This is a randomized, parallel group study of bright light treatment versus dim-red light treatment (control group) in PD patients with excessive daytime sleepiness. Thirty subjects will be enrolled and randomized 1:1 to bright light or dim-red light exposure.
STUDY SUBJECTS
Subjects will be screened and recruited from the Northwestern University Parkinson's Disease and Movement Disorders Center, which evaluates over 700 PD patients annually, and the Rush University Movement Disorders Center, which evaluates over 1000 PD patients annually. The study protocol will be approved by the Institutional Board Reviews of Northwestern and Rush University. All study related procedures / visits will take place at Northwestern University. Written consent will be obtained from all subjects prior to enrollment.
Inclusion criteria will be: diagnosis of idiopathic PD as defined by the United Kingdom Parkinson's Disease Society Brain Bank Criteria; Hoehn and Yahr stage of 2 to 4 in the "on" state; excessive daytime sleepiness as defined by the Epworth Sleepiness Scale (ESS) score of greater than or equal to 12 points; stable PD medication regimen for at least 4 weeks prior to study screening; a reliable bed partner / caregiver who can observe the patient during the night.
Exclusion criteria will be: atypical parkinsonian syndromes; significant sleep disordered breathing (defined as an apnea-hypopnea index >15 events/hr of sleep on screening PSG), significant periodic limb movement disorder (defined as a PLM arousal index>10 events/hr of sleep on screening PSG), and REM sleep behavior disorder (based on the presence of both clinical symptomatology as well as intermittent loss of REM atonia on screening PSG); cognitive impairment indicated by the mini-mental status examination (MMSE) score of less than 24; untreated hallucinations or psychosis (drug-induced or spontaneous); use of hypno-sedative drugs for sleep or stimulants during the daytime; use of antidepressants unless the patient has been on a stable dose for at least three months; visual abnormalities that may interfere with light therapy, such as significant cataracts, narrow angle glaucoma or blindness; travel through 2 time zones within 90 days prior to study screening.
STUDY PROTOCOL
Screening visits At screening, potential study subjects will be evaluated for inclusion and exclusion criteria. Subjects meeting entrance criteria will be invited to participate and sign informed consent. All subjects will have neurological and ophthalmologic examination, Hoehn and Yahr staging, The United Parkinson's Disease Rating Scale (UPDRS) and MMSE. Subjects will also complete a set of questionnaires, including ESS, The Parkinson's Disease Sleep Scale (PDSS), The Pittsburgh Sleep Quality Index (PSQI), The Berlin Questionnaire, The Fatigue Severity Scale (FSS), The Beck Depression Inventory (BDI) and The PDQ38 (PD-specific quality of life scale). Subjects will subsequently be scheduled for a polysomnogram (PSG) and the Multiple Sleep Latency Test (MSLT) at the General Clinical Research Center at Northwestern Memorial Hospital. PSG will be conducted using standard nocturnal polysomnographic procedures. MSLT will be conducted the following day. PSG will be reviewed and if subjects continue to qualify for the continuation of the study protocol they will be scheduled for the baseline visit. Baseline visit During this visit subjects will be educated how to use an actigraphy monitor and complete daily sleep log and visual analog scale. Baseline phase -weeks 1 and 2 During the baseline phase all subjects will wear an actigraphy monitor with integrated light sensor (Actiwatch-L, Mini-Mitter Co., Inc., Bend, OR, USA), on their non-dominant wrist, 24 hours a day, seven days a week. The Actigraphy monitor will record their activity in epochs of one minute. This monitor has a photosensor that will record light exposure, and therefore allow us to monitor compliance with timed light exposure. Subjects will also complete a sleep log every day, noting time of "lights off", estimated time of sleep onset, any awakenings during the night (>5min), final awakening, and "lights on" time in the morning. Subjects will also complete visual analog scale for daytime sleepiness on Mondays, Wednesdays and Fridays, every two hours, starting at 8am for total of 12 hours. Visit #1 After 14 days of actigraphy monitoring and subjective data collection subjects will return to the office and actigraphy data will be downloaded using the Actiware Software (Mini-Mitter Co., Inc., Bend, OR, USA). Subjects will be equally randomized to bright light and dim-red light treatment. Randomization will employ a random-length permuted block design, with blocks of length 2 and 4. The randomization scheme will be generated in advance, using computer generated, pseudorandom numbers. Subjects will be educated how to use the light box during this visit. Intervention phase -weeks 3 and 4 Subjects will receive one hour of morning (within 9:00-11:00 am) and afternoon (within 5:00-7:00 pm) bright light (10,000lux) or dim red light exposure (<300 lux in gaze direction), daily for two weeks. All subjects will be instructed to keep their face directed towards the light box, without prolonged eye closure. The box will be placed 0.5-1 meter away from the subject. Subjects will record the light exposure duration and timing daily. "SunRay" light boxes (The SunBox Co., Gaithersburg, MD, USA) will be used for light-treatment administration. During the intervention phase all subjects will continue to wear an actigraphy monitor, maintain sleep log, and complete visual analog scale for daytime sleepiness on Mondays, Wednesdays and Fridays, every two hours, starting at 8am for total of 12 hours. After the first week of treatment all subjects will be contacted via phone to screen for potential adverse events. Visit #2 At the end of the intervention phase, all subjects will have final MSLT at the General Clinical Research Center at Northwestern Memorial Hospital. Visit #3 After the completion of the MSLT subjects will return for a follow up evaluation. They will have examination, including the UPDRS and complete ESS, PDSS, PSQI, FSS, BDI and PDQ38. Actiwatches will be returned during this visit and collected data will be downloaded. In order to examine for the carry over effects of initial response to bright light treatment all subjects will continue to maintain sleep logs, and complete visual analog scale for daytime sleepiness on Mondays, Wednesdays and Fridays, every two hours, starting at 8am for total of 12 hours, for additional two weeks. Visit #4 During the final visit sleep diary and visual analog scales will be collected and study subjects will complete ESS, PSQI, PDSS, FSS, BDI and PDQ38.
OUTCOME MEASURES Primary endpoint
The primary outcome measure will be the change in the ESS comparing the bright light exposure with dim-red light exposure.
Secondary endpoints
Secondary outcome measures will include MSLT, the global PSQI score, PDSS score, and actigraphy measures including total sleep time, sleep efficiency, sleep fragmentation index, frequency of naps, and mean activity level (a measurement of daytime function).
A variety of exploratory analyses will examine the effects of bright light exposure on FSS, BDI, quality of life, cognition, and motor disability.
STATISTICAL ANALYSIS Primary endpoint
The distribution of the change scores of the treatment groups will be compared using the Wilcoxon rank-sum test or student's 2-sample t-test, as appropriate. The test will be two-sided, with =0.05.
Secondary endpoint
The distribution of the change scores of the treatment groups will be compared using the Wilcoxon rank-sum test or student's 2-sample t-test, as appropriate. Actigraphy measures will be calculated using the software analysis program provided by Mini-Mitter (Bend, OR) and checked against the daily sleep logs maintained by the subjects. Two-factor repeated measures ANOVA with day of study as the within-subject factor (three time points) and group membership as the between-subject factor will be conducted for actigraphy output measures. Sample size and power The absence of precise preliminary data from previous studies of light therapy in PD using sleep outcomes precludes precise power calculation. With 15 participants per treatment group completing the study protocol, we will have 80% power against an effect size of 1.1( =0.05, two sided, two sample t-test). This corresponds to a mean difference in change scores of around 4.6 on the ESS, if we project a within-group SD of 4 points. The projection is conservatively based on a study of modafinil for the treatment of daytime sleepiness in PD, in which Adler et al. [34] reported within group standard deviations for the change scores ranging from 2.1 to 4.2. We are planning to enroll 15 subjects per treatment group to allow for 20% dropout rate.
